Category: Prevention

Posted on

CDC Get vaccinated even if you had Covid

You should get a COVID-19 vaccine even if you already had COVID-19. No currently available test can reliably determine if you are protected after being infected with the virus that causes COVID-19.

Getting a COVID-19 vaccine after you recover from infection with the virus that causes COVID-19 provides added protection to your immune system. People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19 again than those who get vaccinated after their recovery.

If you currently have COVID-19, you should wait to get your vaccine until your symptoms are gone (if you had symptoms) and you are done with your isolation period. If you are not vaccinated and were exposed to someone with COVID-19, you should wait until your quarantine is over to avoid getting others sick while you get your vaccine.

Note: CDC recommends that all people with HIV get a COVID-19 vaccination, as well as a booster shot when they are eligible. People who are moderately or severely immunocompromised—including those with advanced or untreated HIV—have specific COVID-19 vaccine recommendations, which include an additional primary dose, as well as a booster shot for those eligible. NN: the first line of defense is getting vaccinated unfortunately every 5 or 6 months… It’s your body and your choice…. I believe in the war on Covid you should use ALL the weapons at your disposal. I believe setting the captives free, will be proven to be a colossal mistake by September.

Posted on

niclosamide in preventing the spread and the severity of COVID-19

https://youtu.be/Cjuu5Xw5AcE

A clinical research team at Tufts Medical Center and Tufts University today published the results of the first randomized placebo-controlled clinical trial of the effectiveness of niclosamide, an oral medication long-used worldwide for treatment of tapeworms, in COVID-19 patients. The study, sponsored by Tufts Clinical and Translational Science Institute (CTSI) and funded by the National Institutes of Health (NIH), found that niclosamide did not show a statistically significant reduction in the percentage of adult outpatients with mild to moderate COVID-19 still testing positive at day three, but provided signals of benefit that warrant further study in larger trials. As reported today in JAMA Network Open, Principal Investigator Harry Selker, MD, MSPH, Dean of Tufts CTSI and Executive Director of the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and colleagues, evaluated viral shedding of the virus that causes COVID-19, SARS-CoV-2. The study was conducted using an entirely remote clinical trial platform developed specifically for the study, to avoid requiring patients to have to visit the hospital and to support maintenance of participants’ self-quarantining. Approved by the US FDA for treatment of tapeworm infection in 1982, and used worldwide for 50 years in millions of adults, pregnant women, and children as young as two years old, is included in the World Health Organization (WHO) list of essential medicines, as it is very safe, and it is affordable and widely available. The researchers hypothesized that its antiviral characteristics seen in basic research experiments might prevent the COVID-19 SARS-CoV-2 virus from entering and replicating in human cells. Niclosamide has demonstrated antiviral efficacy across multiple variants of SARS-CoV-2 in laboratory studies, suggesting that it may be effective against COVID-19, including all variants of the virus. Continue reading “niclosamide in preventing the spread and the severity of COVID-19”

Posted on

U.S. FDA considers approving a second COVID-19 booster shot

(Reuters) -U.S. health regulators are looking at authorizing a potential fourth dose of a COVID-19 vaccine in the fall, the Wall Street Journal reported on Saturday, citing sources familiar with the matter. The Food and Drug Administration has been reviewing data to authorize a second booster dose of the messenger RNA vaccines from Pfizer Inc and partner BioNTech SE and vaccines from Moderna Inc, the report added. The agency last month cut the interval to get a booster dose of COVID-19 vaccines from Pfizer and BioNTech as well as from Moderna, in a bid to provide better protection sooner against the Omicron variant. The planning is still in early stages, and authorization would depend on determinations as to whether the second booster should be authorized for all adults or particular age groups, and whether it should target the Omicron variant or be formulated differently, the report said. It added that no decision was final and that it could be necessary to make booster shots available earlier if a new variant appears. The United States reported 2,323 COVID-19 deaths on Friday, bringing the total count to 936,523. NN: It is settled business typical of these types of vaccines like the flue Jap the vaccine wears off very quickly. In the case of the covid vaccines studies show in 4 to 5 months protection drops dramatically Say you get your booster shot in March. That means your timing would be right to receive the modified to new variants that should be available in August or September. Thats when it looks like the new subvariant BA.2 starts infecting people in mass. For the record its a mistake to open things all the way. Have we not learned anything. Every time they open things up within 6 months another wave is upon us. The BA,2 variant is now dominate in South Africa, India, England and Denmark. A recent Denmark study finds its 30% more infectious than the current variant.an it infects more fully vaccinated people then any other variant. This is very early data.

Posted on

Meet your new monster the BA.2 Omicron subvarient

https://youtu.be/PoxC0FQGqFQ

(CNN)The BA.2 virus — a subvariant of the Omicron coronavirus variant — isn’t just spreading faster than its distant cousin, it may also cause more severe disease and appears capable of thwarting some of the key weapons we have against Covid-19, new research suggests. New lab experiments from Japan show that BA.2 may have features that make it as capable of causing serious illness as older variants of Covid-19, including Delta. And like Omicron, it appears to largely escape the immunity created by vaccines. A booster shot restores protection, making illness after infection about 74% less likely. BA.2 is also resistant to some treatments, including sotrovimab, the monoclonal antibody that’s currently being used against Omicron. The findings were posted Wednesday as a preprint study on the bioRxiv server, before peer review. Normally, before a study is published in medical journal, it is scrutinized by independent experts. Preprints allow research to be shared more quickly, but they are posted before that additional layer of review.

Continue reading “Meet your new monster the BA.2 Omicron subvarient”

Posted on

Israeli study offers strongest proof yet of vitamin D’s power to fight COVID

Israel scientists say they have gathered the most convincing evidence to date that increased vitamin D levels can help COVID-19 patients reduce the risk of serious illness or death.Researchers from Bar Ilan University and the Galilee Medical Center say that the vitamin has such a strong impact on disease severity that they can predict how people would fare if infected based on nothing more than their ages and vitamin D levels.

Lacking vitamin D significantly increases danger levels, they concluded in newly peer-reviewed research published Thursday in the journal PLOS One. Continue reading “Israeli study offers strongest proof yet of vitamin D’s power to fight COVID”

Posted on

Japan’s Kowa says Ivermectin showed antiviral effect

TOKYO, Jan 31 (Reuters) – Japanese trading and pharmaceuticals company Kowa Co Ltd (7807.T) on Monday said that anti-parasite drug ivermectin showed an “antiviral effect” against Omicron and other coronavirus variants in joint non-clinical research. The company, which has been working with Tokyo’s Kitasato University on testing the drug as a potential treatment for COVID-19, did not provide further details. The original Reuters story misstated that ivermectin was “effective” against Omicron in Phase III clinical trials, which are conducted in humans. Clinical trials are ongoing, but promotion of ivermectin as a COVID-19 treatment has generated controversy NN: I cannot tell you for sure Ivermectin works. I can tell you for sure it does not hurt. As I sit here taking 3 3mg capsules part of my twice a week routine. Because there is no money in a off patent it will takes years before we have “proof” Well I do not have years since mutation after wave of mutation is coming at me over and over again. So I take Ivermectin as a hedge. I am also FULLY vaccinated. wearing my ugly mask (yes I hear laughter) as day after day I hear reports of N95 toilet paper coffee filter mask user get infected. And I isolate, take my booster vitamins and test. So far only one person on staff has gotten infected and sick Mosh. And he refused to get his vaccine and wore double N95 masks even though he had our ugly masks. And within days of taking Ivermectin the infection cleared and he tested negative… So go figure…

I. Vaccinnate

2. Ivermectin

3. Quarelquinnine

4. Niclosamide

5. Booster Vitamins

Before taking any medicine or supplement consult your medical professional………

Posted on

FDA shortens interval for Moderna booster dose

Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Moderna COVID-19 Vaccine to shorten the time between the completion of a primary series of the vaccine and a booster dose to at least five months for individuals 18 years of age and older.

“The country is in the middle of a wave of the highly contagious omicron variant, which spreads more rapidly than the original SARS-CoV-2 virus and other variants that have emerged,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Vaccination is our best defense against COVID-19, including the circulating variants, and shortening the length of time between completion of a primary series and a booster dose may help reduce waning immunity. Today’s action also brings consistency in the timing for administration of a booster dose among the available mRNA vaccines. We encourage everyone to get vaccinated—it’s never too late to get your COVID-19 vaccine or booster.”

The most commonly reported side effects by individuals who received a booster dose of the Moderna COVID-19 Vaccine after completion of a two-dose primary series were pain, redness and swelling at the injection site, as well as fatigue, headache, muscle or joint pain and chills. The fact sheets for recipients and caregivers and for healthcare providers include information about the potential side effects, as well as the risks of myocarditis and pericarditis.

The amendment to the EUA was granted to ModernaTx Inc.

Moderna Booster Infographic 01072021

Posted on

Best video on supplements. and your immune system

This is the best video i have seen yet on supplements. It is a long play but well worth it

Dr Michael Cohen discusses the importance of Vitamin D and zinc for the optimisation of the immune system. Vitamin K2 is also used to distribute calcium to the correct tissues. explanation of preventing and minimising infection by enabling the amazing natural immune response. NN: We put a lot of time, money and research into our Supplements. Watch the video and then go to our data sheet. CoronaVit Data Sheet You will see why we line up with the supplements spoken about and dosages. If you would like to purchase click this link: Salavida Products